1. Home
  2. XBIT vs SENS Comparison

XBIT vs SENS Comparison

Compare XBIT & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.44

Market Cap

75.0M

Sector

Health Care

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$5.77

Market Cap

213.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
SENS
Founded
2005
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
75.0M
213.2M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
XBIT
SENS
Price
$2.44
$5.77
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$18.38
AVG Volume (30 Days)
22.3K
1.1M
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,389,000.00
Revenue This Year
N/A
$74.15
Revenue Next Year
N/A
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.85
52 Week Low
$2.09
$0.41
52 Week High
$3.61
$8.75

Technical Indicators

Market Signals
Indicator
XBIT
SENS
Relative Strength Index (RSI) 49.74 45.77
Support Level $2.15 $5.26
Resistance Level $2.49 $8.55
Average True Range (ATR) 0.06 0.48
MACD -0.01 0.01
Stochastic Oscillator 26.09 36.46

Price Performance

Historical Comparison
XBIT
SENS

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: